Brionic Spółka z Ograniczoną Odpowiedzialnością (KRS 0000412054, NIP 9721238297) is a Polish company, headquartered in Poznań, Wielkopolskie voivodeship. Brionic operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since February 23, 2012.
Historical suspension of activities
Suspension: March 15, 2022 - resumed: June 2, 2025
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Brionic
Identity
- Name
- Brionic Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- February 23, 2012
- Registry status as of
- November 20, 2025
- Latest entry
- June 2, 2025
- Founding act
- 06.02.2012 R., NOTARIUSZ TOMASZ ANTONIAK, KANCELARIA NOTARIALNA W POZNANIU, REP. A NR 845/2012
Articles of association history (2)
- February 6, 2012: 06.02.2012 R., NOTARIUSZ TOMASZ ANTONIAK, KANCELARIA NOTARIALNA W POZNANIU, REP. A NR 845/2012
- September 25, 2017: 25.09.2017 R., REP. A NR 2246/2017, KANCELARIA NOTARIALNA DR ANDRZEJ RATAJ NOTARIUSZ W POZNANIU, UL. SZEWSKA 18, 61-760 POZNAŃ, ZMIANA § 2, § 10 UST. 1, § 15.
Activities
Other activities
Address and contact
- Address
- POZNAŃ, POLSKA
- Voivodeship
- WIELKOPOLSKIE
- District
- POZNAŃ
- ZAWADZKI@G.PL
- Website
- WWW.BRIONIC.PL
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - Brionic
Credibility rating
50 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
4
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/14 yrs
Board changes
3
3/14 yrs
PKD changes
1
1/14 yrs
Name changes
1
1/14 yrs
Data from 14 years of registry activity.
Credibility history
Payment reliability score from 2021–2023
Current: D (50/100)
Trend: stable (0.0 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2021–2023
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Brionic
Founded
February 23, 2012
14 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
POZNAŃ
WIELKOPOLSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
50 shares total
Shareholders
2
shareholders
Board
1 person
Filed years
3 years
2021–2023
Registry entries
21
latest: June 2, 2025
Revenue
N/A
2023
Net profit
N/A
2023
Assets
N/A
2023
Equity
N/A
2023
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Brionic.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
